Can Patients With Controlled Rheumatoid Arthritis Taper Methotrexate From Targeted Therapy and Sustain Remission? A Systematic Review and Metaanalysis
Pooled result · Ability to sustain remissionResult — go to the resultPooled relative risk 0.90 95% CI 0.84–0.97Authors' conclusion
Patients with controlled RA may taper MTX from targeted therapy with a 10% reduction in the ability to sustain remission for up to 18 months.
Study context
- Population
- Patients with controlled rheumatoid arthritis (RA) on methotrexate (MTX) combined with targeted therapy
- Participants
- 2,000 patients10 studies
- Comparison
- Tapering MTX from targeted therapy vs continuing combination treatment
- Outcome
- Sustained remission after tapering MTX from targeted therapy
Methodological detailsrandom-effects models, 9 randomised studies and 1 observational
- Random-effects models
- 9 randomised studies and 1 observational
Pooled result
Ability to sustain remission
Pooled relative risk
0.90
95% CI 0.84–0.97
MTX taperedvs MTX continued
pooled RR 0.90 (95% CI 0.84–0.97)
As reported in the abstract
- Heterogeneity: I2 = 0%
- P = 0.94
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Can Patients With Controlled Rheumatoid Arthritis Taper Methotrexate From Targeted Therapy and Sustain Remission? A Systematic Review and Metaanalysis. J Rheumatol. Published 15 August 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →